Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer

Condition: Prostate Cancer

Study Type: Observational

Clinical Trials Identifier NCT 8-digits: NCT01059513

Sponsor: Jonsson Comprehensive Cancer Center



  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  • Eligible patients will have clinical stage T1c, T2a, or T2b, a pre-biopsy PSA level <10 ng/mL and a biopsy Gleason score of 3+3 (or 3+4 if fewer than 30% of biopsy cores are involved).
  • The ability to understand and willingness to sign a written informed consent are necessary.

Exclusion Criteria:

  • Patients with tumor parameters that fall outside of the inclusion criteria.
  • Patients with evidence on imagining (bone scan, CT, or MRI) suggestive of disseminated disease.
  • Patients who have had any form of prior prostate treatment (surgery, radiotherapy, cryotherapy, high intensity focused ultrasound, TURP).
  • A prior course of hormone therapy (androgen deprivation) of greater than 3 months duration.
  • The use of other concurrent investigational agents.
  • There are no exclusions due to co-morbid disease or illnesses except for patients with severe inflammatory bowel disease.
  • No life expectancy restrictions will apply.
  • Performance status will not be considered.

View trial on ClinicalTrials.gov